Not yet recruiting
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
NCT07640932· Phase 2· Yonsei University· Source
Contact: Hye Ryun Kim
Not yet recruiting
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840· Phase 3· Asan Medical Center· Source
Contact: JoonNyung Heo, MD, PhD
Recruiting
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
NCT07871435· Phase 1/2· GI Innovation, Inc.· Source
Contact: Sang Joon Shin, M.D., Ph.D. (principal investigator)
Recruiting
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
NCT07493304· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
NCT07340164· Phase 2· Yonsei University· Source
Contact: Jung-Yun LEE, PhD.
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
NCT07147114· Phase 4· Gachon University Gil Medical Center· Source
Contact: Wook-Jin Chung, MD, PhD
Recruiting
Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer
NCT07257523· Phase 2· Yonsei University· Source
Contact: Ik Jae Lee
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Contact: Tae-Gyun Kim, Site 0060
Recruiting
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
NCT07062536· Phase 2· Seoul National University Bundang Hospital· Source
Contact: Choong kun Lee, MD, PhD
Recruiting
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients
NCT07009171· Phase 2· NeuroBiogen Co., Ltd· Source
Contact: Jiwon Lee, Professor
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Contact: Nadene Zack, MS
Active, not recruiting
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· Phase 2· Upstream Bio Inc.· Source
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347· Phase 2· MacroGenics· Source
Contact: Yujeong Huh
Recruiting
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT07172802· Phase 1/2· GI Innovation, Inc.· Source
Contact: Byoung Chul Cho, MD, PhD
Recruiting
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT07246668· Phase 2· Yonsei University· Source
Contact: Ik Jae Lee
Not yet recruiting
CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN
NCT06770426· Phase 3· Yonsei University· Source
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775· Phase 2· TORL Biotherapeutics, LLC· Source
Contact: Principal Investigator
Recruiting
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
NCT07252323· Yonsei University· Source
Contact: Ik Jae Lee
Enrolling by invitation
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
NCT06250777· Phase 2· Yonsei University· Source
Recruiting
Effects of Nutritional Support on Postoperative Delirium
NCT06467552· Yonsei University· Source
Contact: bon nyeo koo, MD
Active, not recruiting
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source
Active, not recruiting
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
NCT06216808· DeepQure Inc.· Source
Recruiting
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
NCT06156527· Phase 2· National Cancer Center, Korea· Source
Contact: Min Hee Hong, Ph,D.
Active, not recruiting
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source
Recruiting
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
NCT05394831· Phase 1/2· J Ints Bio· Source
Contact: Sun Min Lim
Recruiting
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial
NCT05753839· Yonsei University· Source
Contact: Won Sik Ham
Recruiting
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975· Phase 1/2· GI Innovation, Inc.· Source
Contact: Byoung Chul Cho, MD, PhD
Recruiting
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
NCT05782777· Yonsei University· Source
Contact: Byeong-Keuk Kim
Recruiting
Aspirin vs Clopidogrel After TAVR
NCT05493657· Yonsei University· Source
Contact: Young-Guk Ko, MD, PhD
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Recruiting
The COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique
NCT05488665· Yonsei University· Source
Contact: Byeong-Keuk Kim, MD, PhD
Recruiting
PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial
NCT05585411· Yonsei University· Source
Contact: TaeHoon Kim
Recruiting
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
NCT05444270· Yonsei University· Source
Contact: Yong Bae Kim
Active, not recruiting
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
NCT05206812· Phase 2· Yonsei University· Source
Recruiting
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial
NCT05320926· Yonsei University· Source
Contact: Byeong-Keuk Kim
Recruiting
Nutriomics and Artificial Intelligence Nutrition Obesity Cohort
NCT05494138· Yonsei University· Source
Contact: Sungha Park
Active, not recruiting
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
NCT05280457· Phase 2· Yonsei University· Source
Active, not recruiting
Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
NCT05286060· Phase 2· Yonsei University· Source
Active, not recruiting
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016· Phase 2· Amgen· Source
Recruiting
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
NCT04812431· Phase 1/2· S.Biomedics Co., Ltd.· Source
Contact: Dong Ah Shin, MD
Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453· Phase 1/2· GI Innovation, Inc.· Source
Contact: Byoung Chul Cho, M.D., Ph.D. (principal investigator)
Active, not recruiting
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
NCT04676477· Phase 1· Daiichi Sankyo· Source
Recruiting
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
NCT04798690· Dong-A ST Co., Ltd.· Source
Contact: Ho Seong Kim, M.D., Ph.D
Active, not recruiting
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: EUN JI NAM (principal investigator)
Recruiting
Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor
NCT05455918· Phase 2· Yonsei University· Source
Contact: Jung Woo Han
Recruiting
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573· ECOG-ACRIN Cancer Research Group· Source
Contact: Seungmin Bang (principal investigator)
Recruiting
The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit
NCT05415332· Yonsei University· Source
Contact: Chul-Min Ahn
Active, not recruiting
Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage Defects
NCT05440370· L&C Bio· Source
Active, not recruiting
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
NCT04416490· Boryung Pharmaceutical Co., Ltd· Source
Showing 50 of 54.